Severe abnormalities in brain glucose/energy metabolism and insulin signaling have been documented to take a pivotal role in early sporadic Alzheimer's disease (sAD) pathology. Indeed, the "insulin-resistant brain state" has been hypothesized to form the core of the neurodegenerative events that occur in sAD. In this vein, intracerebroventricular administration of subdiabetogenic doses of streptozotocin (STZ) in rats can induce an insulin-resistant brain state, which is proposed as a suitable experimental model of sAD. This review highlights the involvement of disturbed brain insulin metabolism in sAD etiopathogenesis. Furthermore, current knowledge demonstrates that central STZ administration produces brain pathology and behavioral changes that resemble changes found in sAD patients. The STZ-intracerebroventricularly treated rat represents a promising experimental tool in this field by providing new insights concerning early brain alterations in sAD, which can be translated in novel etiopathogenic and therapeutic approaches in this disease.
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Introduction
Alzheimer's disease (AD), the most common form of dementia among older people, affects approximately 35 million people worldwide, and thus is a major health concern in our society (Querfurth and LaFerla, 2010) . AD is clinically manifested by progressive memory loss and a gradual decline in cognitive function, culminating in the premature death of the individual typically 3-9 years after diagnosis (Querfurth and LaFerla, 2010). Neuropathologically, AD is characterized by a dramatic loss of neurons and synapses, especially in the hippocampus and cortex, the extracellular accumulation of neuritic plaques, containing amyloid-␤ (A␤) peptide, and the presence of intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein (Goedert and Spillantini, 2006; Moreira et al., 2009; Moreira et al., 2006; Moreira et al., 2007c; Selkoe, 2001) . Despite indistinguishable clinical dementia symptoms, there are two different types of origin-based AD. In a small proportion (familial early-onset AD), the disease has a genetic origin and is caused by missense mutations in three genes: amyloid-␤ protein precursor (A␤PP), presenilin-1, and presenilin-2 (Rocchi et al., 2003) . Consequently, there is an abnormal and permanent generation of A␤ fragments that deposit as plaques. However, the great majority of AD cases are sporadic in origin, with aging, type 2 diabetes and apolipoprotein E4 as the main risk factors (Hoyer, 2004a) .
Over the last decades, the causes underlying AD pathology have been a "hot topic" in this field. The most prevailing, the "amyloid cascade" hypothesis, proposes that pathological assemblies of A␤ are the cause of both familial (fAD) and sporadic (sAD) forms of AD, whereas other neuropathological alterations are downstream consequences of a gradual aberrant accumulation of A␤ (Hardy and Selkoe, 2002) . In accordance, compelling evidence derived from genetic models clearly demonstrates that severe amyloidosis triggers the fAD pathology (Games et al., 2006; Gimenez-Llort et al., 2007; Hardy and Selkoe, 2002) . However, A␤ has not been proven to be required for the onset and progression of the sAD, thus the "amyloid cascade" hypothesis may not be applicable to sAD (Hoyer, 2004b; Joseph et al., 2001) . A candidate etiological event in sAD is disturbed brain insulin metabolism (Cardoso et al., 2009) . As a matter of fact, it has been reported that early abnormalities in brain glucose/energy metabolism are pronounced in structures with both high glucose demands and high insulin sensitivity, including parietotemporal and frontal areas, which suggests a role for impaired
